Exploring the contribution of COVID-19 prevention network to SARS-CoV-2 vaccine efficacy clinical trials

Glass laboratory flasks on light table

Researchers described the coronavirus disease 2019 (COVID-19) prevention network (CoVPN) and its contribution to clinical efficacy evaluations of COVID-19 vaccines in phase 3 trials.

Eric A. Mellon, M.D., Ph.D., co-leader of Sylvester’s Neurologic Cancer Site Disease Group, associate professor of radiation oncology and biomedical engineering at the Miller School, and co-principal investigator on the grant

Previous article

Get three months of Amazon Music Unlimited and Paramount+ for just $4.99 per month

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News